Donor CHIP and Allogeneic HSCT Outcome

Launched by THE UNIVERSITY OF HONG KONG · Dec 24, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the effects of certain gene mutations in bone marrow donors on the health and recovery of patients receiving stem cell transplants. These transplants, known as allogeneic hematopoietic stem cell transplants (HSCT), can help treat various blood disorders. Researchers want to find out if these mutations, which are common in older adults, can affect how well the transplant works, the chances of the disease coming back, and the overall survival of the patients.

To participate in this trial, you need to be at least 18 years old and either be a donor or a recipient of an allogeneic HSCT. You will need to provide consent for the research team to use your medical information and any leftover samples for further studies. If you join the trial, you can expect to be part of a detailed investigation that aims to improve future treatments for patients undergoing this type of transplant. The study is currently recruiting participants, so if you meet the criteria and are interested, now is a great time to learn more!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult aged 18 year or above
• • 2. Donor and recipient of allo-HSCT
• 3. In prospective and partial prospective/retrospective case, subjects who have provided a signed written informed consent. In retrospective case, subjects who had provided a previously signed written informed consent on:
• • 1. voluntary provision of clinical data, and
• • 2. voluntary provision of archived/remaining specimens for genetic analysis, and
• • 3. authorizing storage and usage of archived/remaining specimens for any further analysis
• Exclusion Criteria:
• • 1. Autologous peripheral blood stem cells or bone marrow stem cell donors for autologous HSCT